"Express Mail" mailing label numberEL 832897714 US
Date of Deposit $7-29-03$
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Printed Name Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: DOUGLAS WADE BEIGHT, ET AL.)
	ying Application Serial No. 09/857,751)
Filed	:) Group Art Unit:) 1625
For	: AROMATIC AMIDES) Examiner:) E.M. Huang
Docket No.	: X-11792B)
Confirmation	No:))

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, under 37 C.F.R. § 1.97(b) Applicants submit an "Information Disclosure Citation in an Application" on a modified Form PTO-1449 for consideration by the Examiner.

As permitted by 37 C.F.R. § 1.98(d), Applicants refer to parent application Serial No. 09/857,751, for copies of the listed documents.

Documents BA, BE - BF and CB-CC on the Form PTO-1449 were cited in the International Search Report of the parent application. A copy of the International Search Report is included with the published application as a part of the Specification on filing.

Other documents listed on the Form PTO-1449 are the following:

Document CA, a review article disclosed at text page 2, lines 25-27, in the description.

Documents AA and AB, U.S. applications from which Document BE, an international application, claims priority. Document AC is a U.S. patent (US 6,140,351) granted on application AB, and Document AC is a U.S. patent (US 6,380,221), which is a divisional of Document AC.

Documents BB and BC, international applications with the same international application date as documents BA and BD.

Each of Documents BA - BD has a U.S. counterpart patent and at least one divisional application pending. Documents BG - BI. further international applications with the same international application date as the instant application, each of which discloses and claims compounds which are factor Xa inhibitors; and each of which has a U.S. application pending. For compliance with 37 C.F.R. § 1.98(2), the following list of patent numbers, publication numbers or serial numbers is provided. It is believed that the published international applications suffice to provide the specification including the claims for the cited applications (some of which are

- 3 -

subject to requirements for restriction and may have divisional applications). However, should more detailed information be required by the Examiner, Applicants will endeavor to provide it promptly.

(Doc)	Document No.	U.S. counterparts & divisionals
(BA)	WO 99/00121	US 6,313,122 B1
		US-2002-0120007-A1 (09/961,164)
(BB)	WO 99/00126	US 6,313,151 B1
		US 6,583,173 B2
		US 6,586,459 B2
(BC)	WO 99/00127	US 6,417,200 B1
		10/133,907
(BD)	WO 99/00128	US 6,372,759 B1
		US 6,500,851 B2
(BG)	WO 00/39092	09/857,748
(BH)	WO 00/39111	09/857,747 (and divisionals)
(BI)	WO 00/39117	09/857,749

It is believed that the subject matter claimed in the instant application is patentably distinct from that of each of the granted US patents and copending applications listed as corresponding to Documents BA - BD and BG - BI; and, moreover, that the subject matter claimed in the instant application and that of each of the applications were, at the time the inventions were made, owned by the same person or subject to an obligation of assignment to the same person.

Applicants request consideration of this information.

Respectfully submitted,

Thomas E. Jackson

Attorney for Applicants Registration No. 33,064

Phone: 317-277-3735

Eli Lilly and Company Patent Division

P.O. Box 6288

Indianapolis, Indiana 46206-6288

Form PTO-1449 (modified) Enclosure:

		<u>Sheet 1 of 2</u>
FORM PTO 1449 (modified)	Atty. Docket No. X-11792B	Div. of Serial No 09/857,751
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Douglas Wade Beight,	et al.
	Filing Date	Group 1624

U.S. PATENT DOCUMENTS

No.	known)	f MM-DD-YY		Applic D	ant of Cited ocument	Lines Releva or R	Columns, s, Where unt Pages elevant es Appear
AA.	00 007 334,204	12,133,					
AB	US 09/187,459	11/1998					
AC	US 6,140,351	10/2000		Arnaiz	, et al.		
AD	US 6,380,221	4/2002		Arnaiz	, et al.		
	FOI	REIGN PATENT	DOCUM	ŒNTS		L	
Cite	Foreign Patent		Name of	Patentee			T ⁶
No.1	Country Code ³ -Number 4-Kind Code5 (if known)	Publication Date MM-DD-YYYY			Where Rele Passages or R	vant elevant	
BA	WO 99/00121	1/1999	WIPO				
BB	WO 99/00126	1/1999	WIPO				
BC	WO 99/00127	1/1999	WIPO				
BD	WO 99/00128	1/1999	WIPO				
BE	WO 99/32477	7/1999	WIPO				
BF	WO 96/28427	9/1996	WIPO				**-
BG	WO 00/39092	7/2000	WIPO				
BH	WO 00/39111	7/2000	WIPO			~~~~	
BI	WO 00/39117	7/2000	WIPO				
BJ			 				
BK			 				
	No. 1 AA AB AC AD Cite No. 1 BA BB BC BD BE BF BG BH BI BJ	No. 1 Number-Kind Code ² (in known) AA US 08/994,284 AB US 09/187,459 AC US 6,140,351 AD US 6,380,221 FOI Cite No. 1 Document Country Code ³ -Number 4-Kind Code5 (if known) BA WO 99/00121 BB WO 99/00127 BD WO 99/00128 BE WO 99/00128 BE WO 99/32477 BF WO 96/28427 BG WO 00/39092 BH WO 00/39111 BI WO 00/39117 BJ WO	No. 1 Number-Kind Code ² (if known) AA US 08/994,284 12/1997 AB US 09/187,459 11/1998 AC US 6,140,351 10/2000 AD US 6,380,221 4/2002 FOREIGN PATENT Country Code ³ -Number 4-Kind Code5 (if known) BA WO 99/00121 1/1999 BB WO 99/00126 1/1999 BC WO 99/00128 1/1999 BC WO 99/00128 1/1999 BE WO 99/32477 7/1999 BF WO 96/28427 9/1996 BG WO 00/39092 7/2000 BH WO 00/39111 7/2000 BJ WO 00/39117 7/2000	Number-Kind Code ² (if known) Number-Kind Code ² (if known)	Number-Kind Code ² (if known)	Number-Kind Code ² (if known)	Number-Kind Code ² (if known) MM-DD-YYYY Applicant of Cited Document Lines Releved or R Pigure

<u></u>			
Examiner	1	Date	i
Signature		Considered	'
SEN ANGINEED LINE	17 1	N D I'm a standard and a standard	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³Enter Office that issued the document, by the two-tetter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precedure the senial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

Sheet 2 of 2

		<u>DNCCC_E OI E</u>	
FORM PTO 1449 (modified)	Atty. Docket No. X-11792B	Div. of Serial No 09/857,751	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Douglas Wade Beight, et al.		
	Filing Date	Group 1624	

, , , ,

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	<pre>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,</pre>	т6	
	CA	Vacca, Joseph P. (Annette M. Doherty Section Editor), Annual Reports in Medicinal Chemistry, (1998), 33, 81-90.		
	СВ	Current Pharmaceutical Design, 1996, 2., "Factor Xa Inhibitors," Kunitada, Satoshi, et al., pages 531-542		
	CC	Katakura, S., et al., Eur. J. Med. Chem., (1995), 30, 387-394		
	CD			
	CE			
	CF			
	CG			
	СН			
	CI			
	CJ			
	СК	·		
	CL			
	CM			
	CN			
	CO			
	CP			

Examiner	Date	
Signature	Conside	red

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

precede the senal number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.